Fig. 1: Analysis of ACP5 levels in Idiopathic pulmonary fibrosis (IPF) patients and mice with bleomycin (BLM) induction.

a ELISA analysis of ACP5 levels in the serum of patients with IPF (n = 20) and control subjects (n = 13, p = 0.0134). b Analysis of the correlation between ACP5 levels with diffusion capacity carbonmonoxide lung (DLCO)% predicted in IPF patients (n = 20, p = 0.0113). c Western blot analysis of ACP5a (p = 0.002) and ACP5b (p = 0.0015), COL1A1 (p < 0.001) and α-SMA (p = 0.001) expression in the lungs of control subjects (n = 5) and IPF patients (n = 5). d Western blot analysis of Acp5a (p < 0.001) and Acp5b (p < 0.001) expression in the lung homogenate of Saline (n = 6) and BLM-induced (n = 6) mouse model. e RT-PCR analysis of Acp5 expression in the lung homogenate from Saline (n = 6) and BLM-induced (n = 11) mice (p < 0.001). f Representative results for coimmunostaining of ACP5 (p = 0.0095) and α-SMA (a myofibroblast marker, p = 0.0059) in the lung sections from patients with IPF (n = 5) and control subjects (n = 5). g Results for coimmunostaining of Acp5 (p < 0.001) and α-SMA (p < 0.001) in the lung sections from Saline (n = 5) and BLM-induced (n = 5) mice. The nuclei were stained blue by DAPI, and the images were taken under original magnification ×400. The data are represented as the mean ± SEM. Two-sided unpaired Student’s t test with Welch’s correction (a, c, d, f, g) and two-sided Student’s t test (b, c, e, f) were applied. *p < 0.05; **p < 0.01; ***p < 0.001. Source data are provided as a Source Data file.